(Total Views: 808)
Posted On: 08/08/2020 3:14:03 PM
Post# of 153903
Shared endpoints vs. Remdesivir
For TechGuru and those who know this information backwards and forwards, does our m2m trial share any specific endpoints vs. remdesivir's, or are they different?
Obviously it would make it significantly easier for CYDY to argue superiority if it's an apples to apples comparison.
It would be the easiest press release in the world to write: Leronlimab Achieves Statistical Superiority to SOC Remdesivir in 6 Crucial Categories.
There. I already wrote the headline.
For TechGuru and those who know this information backwards and forwards, does our m2m trial share any specific endpoints vs. remdesivir's, or are they different?
Obviously it would make it significantly easier for CYDY to argue superiority if it's an apples to apples comparison.
It would be the easiest press release in the world to write: Leronlimab Achieves Statistical Superiority to SOC Remdesivir in 6 Crucial Categories.
There. I already wrote the headline.
(5)
(0)
